Moberg Pharma AB (FRA:MB8) Tariff Resilience Score: 6/10 (As of Jul. 04, 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
60 GF Score
Price €0.80
GF Value €1.05
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Tariff Resilience Score?

Moberg Pharma AB FRA:MB8 +0.50% 60 Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 60/100 and a GF Value™ of €1.05. The stock has 1 warning sign investors should review. Among 1,030 Drug Manufacturers companies, Moberg Pharma AB ranks better than 91.17% on this metric.

Moberg Pharma AB has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Moberg Pharma AB has Moberg Pharma AB has moderate tariff exposure due to its reliance on international suppliers for pharmaceutical ingredients. It has some ability to mitigate through alternative suppliers and pricing strategies. Past tariffs have had a limited impact due to industry-specific exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Moberg Pharma AB might have Average Resilient.

Moberg Pharma AB  (FRA:MB8) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Moberg Pharma AB Tariff Resilience Score Related Terms

FRA:MB8 vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Tariff Resilience Score falls into.


FRA:MB8
60GF Score
Moberg Pharma AB FRA:MB8
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Moberg Pharma AB (FRA:MB8) has a Tariff Resilience Score of 6 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Moberg Pharma AB ranks #91 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Moberg Pharma AB's Tariff Resilience Score too high?
Moberg Pharma AB's current Tariff Resilience Score is 6. Based on the distribution chart, Moberg Pharma AB ranks #91 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #91 out of 1030 companies for Tariff Resilience Score. This places Moberg Pharma AB in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Moberg Pharma AB's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €1.05, compared to a current price of €0.80 — trading 23.6% below its estimated fair value. The current Tariff Resilience Score is 6. Moberg Pharma AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.80 is trading 23.6% below its estimated GF Value™ of €1.05.

Key valuation signals for FRA:MB8:

  • Tariff Resilience Score: 6
  • GF Value™: €1.05 vs. price of €0.80 (23.6% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
60GF Score

Get the complete analysis for FRA:MB8

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€1.05
GF Value